Awiqli, insulin icodec
Named-patient access overview. Awiqli is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Awiqli
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Awiqli
Awiqli (insulin icodec) is manufactured by Novo Nordisk and indicated for Type 2 diabetes (weekly insulin). It is a Weekly basal insulin approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Awiqli
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Awiqli for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Awiqli is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Awiqli in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Awiqli
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.